Search

Displaying results 6561 - 6570 of 10000 in total
  1. Drug

    Lerdelimumab

    go.drugbank.com/drugs/DB06557
    Experimental

  2. Drug

    Triphendiol

    go.drugbank.com/drugs/DB06588
    Experimental

  3. Drug

    Valtorcitabine

    go.drugbank.com/drugs/DB06187
    Investigational

  4. Drug

    Celgosivir

    go.drugbank.com/drugs/DB06580
    Investigational

  5. Drug

    Lactobacillus plantarum

    go.drugbank.com/drugs/DB11360
    Investigational

    *Lactobacillus plantarum* is a member of Lactobacillus, or lactic acid bacteria, that it is widely used in the food industry as a microbial starter and probiotic microorganism. … It is considered to be one of versatile species that carry out fermentative and metabolic processes, while exhibiting an antagonistic activity against pathogenic and spoilage microorganisms.

  6. Drug

    Masitinib

    go.drugbank.com/drugs/DB11526
    InvestigationalVet approved

    Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. … In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.

    Synonyms: 4-((4-METHYLPIPERAZIN-1-YL)METHYL)-N-(4-METHYL-3-((4-PYRIDIN-3-YL-1,3-THIAZOL-2-YL)AMINO)PHENYL)BENZAMIDE
  7. Drug

    Bamifylline

    go.drugbank.com/drugs/DB13203
    Investigational

    Bamifylline is a selective A1 adenosine receptor antagonist.

  8. Drug

    Rivoglitazone

    go.drugbank.com/drugs/DB09200
    Investigational

    Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.

  9. Drug

    Fosinoprilat

    go.drugbank.com/drugs/DB14207
    Experimental

    Fosinoprilat is the active phosphinic acid metabolite of prodrug [fosinopril], which is activated by esterases in vivo. It binds zinc with phosphinic acid group.

  10. Drug

    IP-2018

    go.drugbank.com/drugs/DB19049
    Investigational

    IP-2018 is under investigation in clinical trial NCT04686916 (Clinical Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients).